The aims of this study are to:
1. Identify changes in brain function and structure that correlate with response to
erenumab.
2. Develop models using imaging data +/- clinical data to predict which patients will
respond to erenumab. Pre-treatment and early post-treatment imaging data will be used
separately for predictive modeling.
Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
Terminated
Novartis
Phase 4
2019-12-04
To evaluate the effect of erenumab compared to placebo on disability in employed subjects
with episodic migraine (EM) who have previously failed 1 or more migraine preventive
treatments.
Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
Terminated
Amgen
Phase 4
2019-12-04
To evaluate the effect of erenumab compared to placebo on disability in employed subjects
with episodic migraine (EM) who have previously failed 1 or more migraine preventive
treatments.
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
Recruiting
Amgen
Phase 4
2019-10-07
Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled
study to evaluate the efficacy and safety of erenumab against placebo in subjects with
chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are
diagnosed with medication overuse headache (MOH).
Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH
Recruiting
Amgen
Phase 2
2021-01-04
This is a United States Department of Defense funded Focused Program study that aims to
identify mechanisms and predictors for persistent of post-traumatic headache attributed to
mild traumatic brain injury, and identify methods of preventing post-traumatic headache
persistence.
The objective of the clinical trial component of the Focused Program is to determine whether
intervention with erenumab is an effective treatment for PTH attributed to mTBI.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
